NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(25 sites)

United States

Children's Hospital Colorado, Aurora, Colorado

Rare Disease Research, LLC - FL, Kissimmee, Florida

Rare Disease Research, Atlanta, Georgia

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois

University of Kansas Medical Center (KUMC), Kansas City, Kansas

Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio

The Children's Hospital of Philadelphia (CHOP), Philadelphia, Pennsylvania

University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania

UT Southwestern/Children's Health, Dallas, Texas

Virginia Commonwealth University Health System, Richmond, Virginia

Australia

Perth Children's Hospital, Nedlands, Western Australia

Canada

Alberta Children's Hospital, Calgary, Alberta

British Columbia Children's Hospital, Vancouver, British Columbia

London Health Sciences Centre, London, Ontario

Japan

Fukui Prefectural Hospital, Fukui-shi, Fukui

National Hospital Organization Nagara Medical Center, Nagara, Gifu-shi, Gifu

NHO Osaka Toneyama Medical Center, Toyonaka, Osaka

Shiga General Hospital, Moriyama-shi, Shiga

National Center of Neurology and Psychiatry, Kodaira, Tokyo

New Zealand

Starship Children's Hospital, Auckland

South Korea

Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam

Seoul National University Hospital, Seoul

Turkey (Türkiye)

Ankara Bilkent City Hospital, Ankara

Yeditepe University Kosuyolu Hospital, Istanbul

S.B.U. Dr. Behcet uz Pediatric Diseases and Surgery Training and Research Hospital, Izmir